Live Donor Liver Transplantation with Older Donors Only Impacts on a Late HCV Recurrence.
Abdominal Organ Transplant, Toronto General Hospital, Toronto, ON, Canada.
Meeting: 2016 American Transplant Congress
Abstract number: A201
Keywords: Living-related liver donors
Session Information
Session Name: Poster Session A: Living Donor Liver Transplantation
Session Type: Poster Session
Date: Saturday, June 11, 2016
Session Time: 5:30pm-7:30pm
Presentation Time: 5:30pm-7:30pm
Location: Halls C&D
Introduction:Impact of donor age on HCV recurrence in live donor liver transplant (LDLT) recipients is controversial. We compared HCV progression in recipients receiving a graft from a live donors ≥50 vs < 50 years.
Methods: From 2000-2014, 159 patients with HCV received a LDLT at our institution. Outcomes of patients receiving a graft from donors ≥50 years (LDLT≥50=31) vs <50 years (LDLT<50=128) were compared.
Results: No difference was observed between groups regarding recipient demographics and disease severity. Recipient ICU (LDLT<50:2 vs. LDLT≥50:2 days; p=0.88) and hospital stay (LDLT<50:13 vs. LDLT≥50:16 days; p=0.41) after transplantation was similar. Major complications (Clavien ≥3b) were similar between both groups (LDLT<50:22% vs. LDLT≥50:25%; p=0.63). Rejection episodes did not differ among groups (LDLT<50:25% vs. LDLT≥50:16%; p=0.35). Overall HCV recurrence was similar between both groups (LDLT<50: 56% vs. LDLT≥50: 71%; p=0.15). HCV 1-year recurrence with a METAVIR score ≥2 was also similar (LDLT<50: 10% vs. LDLT≥50: 16%; p=0.35). Although 1-(89%vs.87%), 5-(77%vs.70%) and 10-(71%vs.55%) year graft survival was similar between groups (p=0.096)
, HCV recurrence was the main reason for graft failure in both groups and significantly higher in the LDLT≥50 group (LDLT<50: 21% vs. LDLT≥50: 62%; p=0.002). Late HCV recurrence only manifested itself after 5 years and did not impact on patient survival at 1-(90%vs.90%), 5-(78%vs.69%) and 10-(71%vs.60%) (p=0.25)
.
Conclusion: LDLT with older donors (≥50) for HCV patients resulted in an increased late HCV recurrence. Graft and patient survival remained to be similar when receiving grafts from older vs. younger donors.
CITATION INFORMATION: Goldaracena N, Sapisochin G, Barbas A, Dib M, Al-Adra D, Selzner N, Cattral M, Greig P, Lilly L, McGilvray I, Levy G, Ghanekar A, Renner E, Grant D, Selzner M. Live Donor Liver Transplantation with Older Donors Only Impacts on a Late HCV Recurrence. Am J Transplant. 2016;16 (suppl 3).
To cite this abstract in AMA style:
Goldaracena N, Sapisochin G, Barbas A, Dib M, Al-Adra D, Selzner N, Cattral M, Greig P, Lilly L, McGilvray I, Levy G, Ghanekar A, Renner E, Grant D, Selzner M. Live Donor Liver Transplantation with Older Donors Only Impacts on a Late HCV Recurrence. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/live-donor-liver-transplantation-with-older-donors-only-impacts-on-a-late-hcv-recurrence/. Accessed July 12, 2025.« Back to 2016 American Transplant Congress